differentially methylated in LG and HG BC using two different genomewide methylation-profiling platforms. Multivariable logistic regression prediction models were created.
INTRODUCTION AND OBJECTIVES:
Bladder cancer is one of the most expensive neoplasm. Recurrences rates achieves 50% of the patients at 5 years. After TUR BT is performed, many pacients experiment lower urinary tract syntomatology.Low risk non-muscle invasive bladder cancer (NMIBC) is an heterogeneous neoplasm, characterized by a high percentage of recurrences but a low tendency of progression. In this group of patients, overtreatment posts and impact in the quality of life and it implies high significant economical costs and an important deterioration of the quality of life, without evidence of improving their survival. Our aim is to report our experience with low-risk bladder cancer patients under an active surveillance program after cancer recurrence, and to analyse which variables might help to predict progression.
METHODS: From 2006 we have offered the option of active surveillance to all low risk tumours at time of recurrence. Follow-up included flexible cystoscopy and cytology every six months. TUR was performed when tumour size or number of lesions increased, at high grade cytology, when hematuria, tumour aspect worsened or patients' choice.
RESULTS: 91 patients were included. Mean age at recurrence was 71.5 years. Only 19% were female. Most patients received immediate postoperative mytomicin C (84.61%). Histological initial features were stage pTa in 54.9%, stage pT1a in 9.9%, pTx in 4.4% and PUNLMP in 5.5% and papilloma in 2.2%; all were low grade. Mean time between TUR and recurrence was 51.53 months. The mean follow-up was 95.35 months.
65 patients (71.4%) underwent TUR after recurrence (mean time 28 months). Main cause of TUR (23%) was urologist decision, tumor size (13%), 13% due to hematuria,10% due to increased number of lesions, 10% was a patient's decision to stop the surveillance and 6.1% to positive cytology.
Concerning recurrence features, 80.2% were single tumors and size was 5 mm in 85%. Sixteen patients (17.58%) progressed in grade and 20.87% in T stage (pTa to pT1a/b). Only 5 patients progressed to pT1b (5.49). Cytology was not able to detect all the grade progressions. At the time of final TURBT, 50.76% presented multiple (>2) lesions in the bladder.
None of our patients progressed to muscle invasive bladder cancer.
High grade cytology was only presented in 25% of the final high grade tumours.
CONCLUSIONS: Patients with recurrent, small, non muscleinvasive bladder tumours can be safely offered monitoringunder an active surveillance protocol.
Active surveillance can be safely considered in patients with less than 5mm recurrence or negative cytology, although cytology cannot clearly predict grade progression in this group of patients. Table) . BCG claims were characterized as induction or maintenance. Adequate BCG was defined by ! 1 induction (! 5 instillations) and ! 1 maintenance (! 2 instillations) course; otherwise, treatment was considered inadequate. Exploratory landmark survival analyses at 6, 12, and 18 months (mo) using multivariate Cox models assessed associations between BCG treatment intensity and recurrence, progression, and cancer-specific and overall mortality by risk group. Recurrence and progression proxies were defined using treatment and procedure claims.
RESULTS: 39,532 NMIBC pts met selection criteria and were mostly male (75%) with mean age of 78 y (risk group: low, 48%; intermediate, 16%; high, 36%). z 41% received BCG, which was more common among intermediate-(52%) and high-(53%) than low-risk (28%) pts. Few BCG-treated pts received adequate treatment: low-risk, 26%; intermediate-, 30%; and high-, 29%. Across risk groups, adequately treated pts were slightly younger and healthier than those with inadequate treatment. At the 12-mo landmark across risk groups, increased BCG treatment intensity was associated with decreased risk of recurrence, but not progression; increased BCG treatment intensity was also associated with decreased cancer-specific and overall mortality in intermediate-and high-risk pts, but not low-risk pts (Table) . Trends at the 6-and 18-mo landmarks were generally similar.
CONCLUSIONS: Half of intermediate-and high-risk NMIBC pts do not receive BCG, and of those who do, few receive adequate treatment, suggesting adherence to guidelines for NMIBC management is lacking. In pts receiving BCG, adequate treatment intensity appears to improve outcomes.
